investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma

Roberto Chiarle

3 Collaborator(s)

Funding source

National Cancer Institute (NIH)

Feng Zhang

Broad Institute

Cambridge, United States

Hanno Steen

Boston Children's Hospital

Boston, United States

Related projects

Ann M Moormann

Impact of Malaria on Shaping Immunity to EBV in the Etiology of Burkitt lymphoma

Non-Hodgkin lymphoma

Pathology Hematology and hematologic malignancies

William Figg

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology

Tracy L Mcgaha

The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development

Non-Hodgkin lymphoma

Pathology Hematology and hematologic malignancies

Dipanjan Chowdhury

Molecular mechanism and relevance of microRNAs in DSB repair pathway choice

Non-Hodgkin lymphoma

Pathology Hematology and hematologic malignancies

John Nicholas

BH3-only Protein Targeting by HHV-8

Non-Hodgkin lymphoma

Pathology

Nathanael S Gray

MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL

Non-Hodgkin lymphoma

Pathology Hematology and hematologic malignancies

Louis Staudt

Molecular Diagnosis and Outcome Prediction in Lymphoma

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology

Elliott D Kieff

Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation

Non-Hodgkin lymphoma

Pathology

Elaine Jaffe

Lymphoma Disease Discovery and Definition

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology